Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hayes KC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ca611cb145b34bab91b18fb7e442dcf5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca611cb145b34bab91b18fb7e442dcf5
record_format	dspace
spelling	oai:doaj.org-article:ca611cb145b34bab91b18fb7e442dcf52021-12-02T03:46:25ZImpact of extended-release dalfampridine on walking ability in patients with multiple sclerosis1176-63281178-2021https://doaj.org/article/ca611cb145b34bab91b18fb7e442dcf52011-04-01T00:00:00Zhttp://www.dovepress.com/impact-of-extended-release-dalfampridine-on-walking-ability-in-patient-a7273https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&nbsp;4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials demonstrated significant improvements in walking in patients with the four primary forms of MS following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby leading to improved neurological function. This review describes how dalfampridine represents a new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on their gait disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well and their improvement in terms of household and community ambulation, inferred from analysis of pooled data from several studies, is likely to translate into benefits in the performance of instrumental activities of daily living and a reduction in the neuropsychiatric burden of disease.Keywords: dalfampridine ER, Ampyra&reg;, fampridine-SR, 4-aminopyridine, multiple sclerosis, demyelinationHayes KCDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 229-239 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hayes KC Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
description	Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&nbsp;4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials demonstrated significant improvements in walking in patients with the four primary forms of MS following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby leading to improved neurological function. This review describes how dalfampridine represents a new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on their gait disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well and their improvement in terms of household and community ambulation, inferred from analysis of pooled data from several studies, is likely to translate into benefits in the performance of instrumental activities of daily living and a reduction in the neuropsychiatric burden of disease.Keywords: dalfampridine ER, Ampyra&reg;, fampridine-SR, 4-aminopyridine, multiple sclerosis, demyelination
format	article
author	Hayes KC
author_facet	Hayes KC
author_sort	Hayes KC
title	Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
title_short	Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
title_full	Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
title_fullStr	Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
title_full_unstemmed	Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
title_sort	impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/ca611cb145b34bab91b18fb7e442dcf5
work_keys_str_mv	AT hayeskc impactofextendedreleasedalfampridineonwalkingabilityinpatientswithmultiplesclerosis
_version_	1718401645622067200

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Ejemplares similares